Evaluating bimekizumab safety

Br J Dermatol. 2024 Mar 15;190(4):458-459. doi: 10.1093/bjd/ljad451.

Authors

Katie Lovell¹, Steven R Feldman^{1

2

3}

Affiliations

¹ Departments of Dermatology.
² Pathology.
³ Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

PMID: 37979159
DOI: 10.1093/bjd/ljad451

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized*
Humans

Substances

bimekizumab
Antibodies, Monoclonal, Humanized